

AMENDMENTS TO THE SPECIFICATION:

Please cancel the originally-filed Abstract of the Disclosure, and add the accompanying new Abstract of the Disclosure which appears on a separate sheet in the Appendix.

Page 1, before line 1, insert the following:

--This application is a national phase application of PCT/EP2005/001458, filed on February 14, 2005.--

Page 2, between lines 26 and 27, insert the following:

--BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the results of a proliferation assay.

Figure 2 shows the results of a permeability assay.--

Page 3, replace the paragraph beginning on line 4 with the following amended paragraph:

--It is therefore an object of the present invention disclosure to illustrate the use of o-ATP for the inhibition of angiogenesis. In particular, the invention provides a medicament containing o-ATP as the active principle, useful for the treatment of pathologies, the onset or progression of which involves angiogenesis. The angiogenesis-mediated diseases that can benefit from the treatment with o-ATP according to the invention include neovascularization-induced ocular diseases, such as diabetic retinopathy, macular degeneration, proliferative vitreoretinopathy, glaucoma, atherosclerotic processes and tumours, such as carcinomas, lymphomas, leukaemia, sarcomas, melanomas, gliomas, neuroblastomas and other solid tumours.--